Investors eyeing a purchase of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock, but tentative about paying the going market price of $14.27/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the November put at the $11 strike, which has a bid at the time of this writing of $1.65. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock performance was 1.15% in last session and finished the day at $14.06. Traded volume was million shares in the last session and the average volume of the stock remained 1.12million shares. The beta of the stock remained -0.34. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider ownership is 1.10%.

The Medicines Company (NASDAQ:MDCO) has announced that the US Food and Drug Administration (FDA) has accepted the filing of a biologic license application (BLA) for the investigational hemostatic agent Fibrocaps, a dry powder formulation of fibrinogen and thrombin being developed to aid in hemostasis during surgery, where control of mild or moderate bleeding by conventional means is ineffective or impractical. The Medicines Company (NASDAQ:MDCO) rose 3.14 percent to $25.00 Tuesday on volume of 1.04million shares. The intra-day range of the stock was $23.95 to $25.04. The Medicines Company (NASDAQ:MDCO) has a market capitalization of $1.62billion.

Avanir Pharmaceuticals Inc (NASDAQ:AVNR) reported that the New Drug Application (NDA) for its migraine candidate, AVP-825 has been authorized by the U.S. Food and Drug Administration (FDA). The NDA was filed based on data from a pivotal phase III trial in addition to a phase II trial down with two pharmacokinetic studies on AVP-825. Avanir Pharmaceuticals Inc (NASDAQ:AVNR)’s stock on Apr 08, 2014 reported a increase of 3.18% to the closing price of $3.57. Its fifty two weeks range is $2.60 -$6.00. The total market capitalization recorded $543.70million. The overall volume in the last trading session was 1.90million shares. In its share capital, AVNR has 152.28million outstanding shares.

Just days ago Deerfield stepped in as a new investor for Kolltan, a New Haven, CT-based biotech developing cancer therapies, putting up part of a $60 million D round. It recently provided a $35 million loan, in tranches, to Cytomedix, offered up to $250 million in a bridge loan so that Horizon Pharma Inc (NASDAQ:HZNP) can buy Vidara and bought a chunk of Infinity Pharmaceuticals’ ($INFI) stock, also providing a $100 million credit facility to back its development work. On Tuesday, shares of Horizon Pharma Inc (NASDAQ:HZNP) dropped -0.44% to close the day at $13.45. Company return on investment (ROI) is -67.70% and its monthly performance is recorded as -0.96%. Horizon Pharma Inc (NASDAQ:HZNP) quarterly revenue growth is 57.31%.